Trials / Completed
CompletedNCT01179672
A Study in Participants With Diabetic Peripheral Neuropathic Pain in China
Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China: Duloxetine Versus Placebo
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 405 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to assess the efficacy of duloxetine 60 milligrams (mg) once daily (QD) compared with placebo, on the change in pain severity from baseline to 12 weeks as measured by the weekly mean of the daily pain scores recorded in the participant's diary in participants with diabetic peripheral neuropathic pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Duloxetine | 30 mg administered orally (po), QD for 1 week; 60 mg administered po, QD for remaining 11 weeks; 30 mg administered po, QD for 1 week during taper period |
| DRUG | Placebo | Administered po, QD for 12 weeks; administered po, QD for 1 week during taper period |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2013-08-01
- Completion
- 2013-08-01
- First posted
- 2010-08-11
- Last updated
- 2014-10-13
- Results posted
- 2014-07-14
Locations
15 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01179672. Inclusion in this directory is not an endorsement.